Oakworth Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Oakworth Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,081	Closed	-$241K	–	727
2023 Q3	$241K	Hold	2,081	–	–	0.02%	149
2023 Q2	$214K	Hold	2,081	–	–	0.02%	162
2023 Q1	$227K	Hold	2,081	–	–	0.02%	158
2022 Q4	$237K	Hold	2,081	–	–	0.02%	138
2022 Q3	$129K	Hold	2,081	–	–	0.01%	201
2022 Q2	$166K	Buy	2,081 +1,763	+554%	+$167K	0.02%	180
2022 Q1	$33K	Hold	318	–	–	﹤0.01%	340
2021 Q4	$34K	Hold	318	–	–	﹤0.01%	371
2021 Q3	$35K	Hold	318	–	–	﹤0.01%	352
2021 Q2	$30K	Hold	318	–	–	﹤0.01%	370
2021 Q1	$29K	Hold	318	–	–	﹤0.01%	365
2020 Q4	$23K	Hold	318	–	–	﹤0.01%	357
2020 Q3	$25K	Hold	318	–	–	﹤0.01%	348
2020 Q2	$18K	Hold	318	–	–	﹤0.01%	362
2020 Q1	$9K	Hold	318	–	–	﹤0.01%	392
2019 Q4	$12K	Hold	318	–	–	﹤0.01%	421
2019 Q3	$9K	Buy	+318	New	+$8.22K	﹤0.01%	453
2019 Q2	–	Sell	-318	Closed	-$8K	–	671
2019 Q1	$8K	Buy	+318	New	+$7.54K	﹤0.01%	477

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Oakworth Capital's HZNP Position: Q4 2023 in Review

Oakworth Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,081 shares — an estimated $241K sold.

Oakworth Capital first reported a position in HZNP in Q1 2019 and held it in 18 quarters. The position peaked at $241K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Oakworth Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Oakworth Capital sold 2,081 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $241K.
Oakworth Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 18 quarters.
Oakworth Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $241K in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Oakworth Capital's 13F filing for Q4 2023, filed 31 Jan 2024.